carmofur has been researched along with Cancer of Ovary in 7 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " HCFU might be effective against gynecologic cancers when used in maintenance therapy at a lower dosage (300--400 mg) than previously estimated." | 1.27 | Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue. ( Matsui, Y; Okudaira, Y; Sawada, M, 1983) |
| "Furthermore, the 5-FU level in ovarian cancer tissues was much higher than that in the tissues of the contralateral normal ovary, suggesting that degradation of 5-FU might be delayed in cancer tissue." | 1.27 | [Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors]. ( Iguchi, T; Ino, Y; Isono, T; Sato, M; Takeda, Y; Takizawa, K; Yokoo, I, 1988) |
| " Even so, HCFU should be dosed when needed in spite of this risk." | 1.27 | [A case of leukoencephalopathy caused by HCFU]. ( Abe, S; Kamata, H; Kisida, S; Miyagawa, N; Murakami, A; Nagano, H; Ueda, K; Yasui, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Noda, T | 1 |
| Kosakai, H | 1 |
| Tsujimura, K | 1 |
| Nakanishi, A | 1 |
| Shintani, M | 1 |
| Kamamoto, Y | 1 |
| Shimamoto, I | 1 |
| Ichijo, M | 1 |
| Sawada, M | 3 |
| Matsui, Y | 1 |
| Okudaira, Y | 1 |
| Sipilä, P | 1 |
| Kivinen, S | 1 |
| Gröhn, P | 1 |
| Vesala, J | 1 |
| Heinonen, E | 1 |
| Takizawa, K | 1 |
| Ino, Y | 1 |
| Isono, T | 1 |
| Sato, M | 1 |
| Yokoo, I | 1 |
| Iguchi, T | 1 |
| Takeda, Y | 1 |
| Kamata, H | 1 |
| Murakami, A | 1 |
| Miyagawa, N | 1 |
| Yasui, H | 1 |
| Nagano, H | 1 |
| Abe, S | 1 |
| Ueda, K | 1 |
| Kisida, S | 1 |
| Ozaki, M | 1 |
| Hongo, J | 1 |
| Hirota, Y | 1 |
| Inagaki, M | 1 |
1 trial available for carmofur and Cancer of Ovary
| Article | Year |
|---|---|
[Clinical trial of carmofur (HCFU) in the treatment of malignant ovarian cancer--The first report: combination therapy with endoxan, mitomycin C, and toyomycin].
Topics: Adult; Aged; Antineoplastic Agents; Chromomycin A3; Clinical Trials as Topic; Cyclophosphamide; Drug | 1983 |
6 other studies available for carmofur and Cancer of Ovary
| Article | Year |
|---|---|
Concentrations of a new antitumor agent, 1-hexylcarbamoyl-5-fluorouracil in serum and gynecologic tumor tissue.
Topics: Antineoplastic Agents; Female; Fluorouracil; Humans; Ovarian Neoplasms; Uterine Cervical Neoplasms | 1983 |
Phase II evaluation of peroral carmofur, cyclophosphamide, and hexamethylmelamine as a second-line therapy in advanced epithelial ovarian carcinoma.
Topics: Administration, Oral; Adult; Aged; Altretamine; Antineoplastic Combined Chemotherapy Protocols; Carc | 1989 |
[Experimental chemotherapy of ovarian cancers heterotransplanted in nude mice].
Topics: Adenocarcinoma, Mucinous; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1985 |
[Estimation of 1-hexylcarbamoyl-5-fluorouracil (HCFU) and 5-FU concentrations in sera and resected specimens from patients with ovarian tumors].
Topics: Administration, Oral; Female; Fluorouracil; Humans; Ovarian Neoplasms; Ovariectomy; Ovary; Uterus | 1988 |
[A case of leukoencephalopathy caused by HCFU].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; B | 1988 |
[Effect of post operative maintenance chemotherapy against ovarian cancer].
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Female; Fluorouracil; Humans; Mice; Mice, | 1987 |